BRIDGEWATER, NJ – Bausch + Lomb, a leading global eye health company, today announced the introduction ofPeroxiClear™ 3% hydrogen peroxide cleaning and disinfecting solution, the most advanced* peroxide-based lens care solution to launch in years. The solution offers a welcome alternative peroxide-based product. PeroxiClear solution has been proven to keep contact lenses cleaner and moister for longer.1-3 

“We’ve been hearing from many doctors that there’s been an increasing need to address their patients’ contact lens discomfort. Bausch + Lomb is proud to now provide an alternative option and innovation with PeroxiClear,” said Joseph Barr, OD, MS, FAAO, vice president, Medical Affairs, Pharmaceuticals & Vision Care, Bausch + Lomb. “Bausch + Lomb’s mission has always been to help patients see better to live better, and with the introduction of PeroxiClear cleaning and disinfecting solution, we can now offer them the most advanced peroxide-based lens solution on the market today.”

PeroxiClear solution is a unique formula that contains Triple-Moist Technology™, which helps to provide up to 20 hours of moisture.1 PeroxiClear provides the disinfection efficacy you expect from a hydrogen peroxide solution, but neutralizes in only four hours, as compared to six with other peroxides.

“PeroxiClear solution is the most-advanced peroxide-based solution that I’ve used in years,” said Brad Oatney, O.D. “WithPeroxiClear solution, I can continue to offer my patients the best in eye care products, which is always my primary goal.”

With the introduction of PeroxiClear solution, Bausch + Lomb now has products in each key segment of the lens care business, including Boston® rigid gas permeable lenses, Biotrue® and renu® multi-purpose solutions, and peroxide-based care.

PeroxiClear solution will be available in major retailers starting in April and May 2014, including Target, Rite-Aid, K-Mart, Walmart, Walgreens and CVS.  It will be available at most retailers nationwide by June 2014.

About Bausch + Lomb:
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries.

REFERENCES:
1 High-resolution/accurate-mass (HR/AM) mass spectrometry was used to detect and quantitate the relative amounts of surfactant retained on lenses from PeroxiClear™ and Clear Care solutions after 20 hours of wear. PureVision®2, ACUVUE OASYS, and AIR OPTIX AQUA lenses were soaked in solutions for 12 hours prior to patients wearing lenses for 20 hours. 
2  Results of an ex vivo study measuring deposits on worn contact lenses to compare the clinical performance of PeroxiClear™ and Clear Care solutions. Lenses were worn daily for 1 month (silicone hydrogel and Group IV hydrogel lenses) or 3 months (gas permeable lenses). A total of 374 lenses were randomly selected for image analysis. Lenses were scored for mean density of deposits and percent coverage of deposits.
3 Results of an in vitro study measuring deposits on ACUVUE OASYS lenses. Lenses were subjected to 14 cycles of deposition with a lipid and protein solution mimicking the human tear film followed by a cleaning regimen with either PeroxiClear™ or Clear Care 3% hydrogen peroxide systems. Each deposition/cleaning cycle was representative of one day of patient use. Cycled lenses (n=3) were analyzed for deposits using image analysis. After 14 cycles, lenses cleaned with PeroxiClear™ had only 8.0% surface coverage compared to 33.0% for lenses cleaned with Clear Care.

*Compared to Clear Care
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates. 
All other product/brand names are trademarks of their respective owners.